Target Therapy vs the Immune Check Point Inhibitors in Lung Cancer: Costs and Caps Platform
Main Article Content
Abstract
The immune check point inhibitors (ICI) and target therapy (TT) Osimertinib (Osi) prolonged survival in advanced/metastatic non-small cell lung cancer (a/m-NSCLC). Costs of ICI were previously investigated (ESMED, July 2022) while TT being overlooked. In 2022, insulin monthly cost was capped at $35 for Medicare patients. We aimed to 1- Attach a $ amount to results of the major relevant TT and ICI clinical studies and weigh their relative costs 2- Reason that utilization threshold caps are necessary to contain cost of extended therapy
Methods: In this prospective observational study, annual costs of the approved and widely used TT were calculated as the monthly optimal dose x 12. Costs of the 5-approved ICI in 1-st-line a/m NSCLC were calculated as mg/m2 or per 80 kg x price x number of cycles.
Results: Median annual 5-TT cost was $228,000 vs 5-ICI of $134,786 at 1.69 ratio. At 10%, estimated coverage of pharmacy and nursing costs, ratio dropped to 1.52. The 1-3-year Osi costs were $248,372-$745,116, Crizotinib $226,308 -$678,924 and Larotrectinib $399,372-$1,198,116. Pembrolizumab were $134,796-$404,388, Atezolizumab $124,761-$374,283 and Cemiplimab $125,108-$375,324.
Applying $500,000 caps, the ICI 3-year costs were all below threshold. TT medium 3-year cost was $684,000, exceeding cap by $184,000, Osi by $245,116 and Crizotinib by $178,924. Larotrectinib 2-3-year costs were higher by $298,744 - $698,116. We reasoned that if 1,000 US patients treated with TT at the annual median, cost mounts to $684,000,000. In Europe, 2,000 patients’ cost would be $1,368,000,000.
Conclusions: The median TT/ICI was more costly at 1.52 ratio. Drug costs were determined by the number of re-purchases, the 1st-buy, if followed, was considered a down payment. Cap implementations are necessary to contain costs of extended therapy.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2-Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med. 2015; 372:2018–28.
3-Garon EB, et al. Pembrolizumab monotherapy 5-year data from KEYNOTE-001 in patients with advanced non–small cell lung cancer (NSCLC), ASCO annual meeting, Chicago, May 2019 (Abstract LBA9015)
4- Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small lung cancer. N Engl J med. 2016: 375:823-833.
5- Reck M, Rodriguez-Abreu D. Updated analysis of KEYNOTE-024: Pembrolizumab vs. platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. JCO 37, 7, 537-546, 2019.
6-Herbst RS, Gluseppe G, de Marinis F, et al, Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. NEJM. 2020, 383,1328-1339.
7-Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 397(10274):592-604, 2021
8- Chihara Y, Takeda T, Goto Y, et al. Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC in elderly patients. The oncologist. 27, no 11, November 2022
9- Wu Yi-L, Tsuboi M, He J, et al. Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA. Presented at: ESMO Congress 2022; September 9-13, 2022; Paris, France.
10- Li M, Liao K, Pan I-Wen et al. Growing Financial burden from high cost targeted oral anticancer medicines among Medicare beneficiaries with cancer. JCO oncology practice ,18,11,759, 2022
11- OU Si, Zhu VW. CNS metastasis in ROS1 +NSCLC: an urgent call to action, to understand, and to overcome lung cancer. 130, 201-207; 2019
12- World Health Organization- International Agency for Research on Cancer. World Fact Sheet. Available at https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed May 2020.
13-Hartman M, et al. Health Aff. (Millwood). 2021; doi:10.1377/hlthaff.2021.01763. The Centers for Medicare & Medicaid Services ( CMS). National Health Care Spending In 2020: Growth Driven By Federal Spending In Response To The COVID-19 Pandemic.
14-Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: Revisions and reflections in response to comments Received. J Clin Oncol. May 31,2016. 18-
15-Cherny NI, Dafni U, Bogaerts J, et al. ESMO- Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340- 2366. doi:10.1093/annonc/mdx310PubMedGoogle
16-Siegel JE, Weinstein MC, Russell LB, et al. Panel on cost-effectiveness in health and medicine. Recommendations for reporting cost effectiveness analyses. JAMA. 1996;276(16):1339–1341
17-Subbiah V et al. Prevalence of RET fusion in cancer. J Clin Onc 2020,38: 1209-1221
18- Guirgis, HM. Drug Costs vs. Probability of Survival in Lung Cancer, Impact of Dosage, Duration, and Immune Check Point Inhibitors Combinations. JCP 5, 32-36, 2019. Doi:10.25270/jcp.2019.06.00083
19-Guirgis, HM. Costs of extended immune check point inhibitors treatment in advanced/metastatic lung cancer: Bundling of cost proposal. ASCO May-June 2020 annual meeting, Chicago, abstract 291815
20-Kline RK. Bundled Payment Models in Oncology: Learning to Think in New Ways DOI: 10.1200/OP.20.00735 JCO Oncology Practice, Published online February 04, 2021, PMID: 33539197
21-Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Eng/ J Med. 2017; 377:829-838.
22-Solomon BJ, Besse B, Bauer TM, et al: Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study. Lancet Oncol 19: 1654-1667, 2018